Identification of a Lipid Metabolism-Associated Gene Signature Predicting Survival in Breast Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Baenke F, Peck B, Miess H, et al. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech. 2013;6(6):1353–1363. doi:10.1242/dmm.011338
   PubMed Web of Science ®Google Scholar
• Guerra B, Issinger OG. Role of protein kinase CK2 in Aberrant lipid metabolism in cancer. Pharmaceuticals (Basel). 2020;13(10):10. doi:10.3390/ph13100292
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47. doi:10.1016/j.cmet.2015.12.006
   PubMed Web of Science ®Google Scholar
• Giridhar KV, Liu MC. Available and emerging molecular markers in the clinical management of breast cancer. Expert Rev Mol Diagn. 2019;19(10):919–928. doi:10.1080/14737159.2019.1664901
   PubMed Web of Science ®Google Scholar
• Wang G, Zhan T, Li F, et al. The prediction of survival in gastric cancer based on a robust 13-gene signature. J Cancer. 2021;12(11):3344–3353. doi:10.7150/jca.49658
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–52. doi:10.1093/nar/gku1003
   PubMed Web of Science ®Google Scholar
• Duan J, Soussen C, Brie D, et al. Generalized LASSO with under-determined regularization matrices. Signal Processing. 2016;127:239–246. doi:10.1016/j.sigpro.2016.03.001
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–29. doi:10.1038/75556
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. doi:10.1093/nar/28.1.27
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5(1):e189. doi:10.1038/oncsis.2015.49
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200. doi:10.1126/sciadv.1600200
   PubMed Web of Science ®Google Scholar
• Jiang P, Yang F, Zou C, et al. The construction and analysis of a ferroptosis-related gene prognostic signature for pancreatic cancer. Aging (Albany NY). 2021;13(7):10396–10414. doi:10.18632/aging.202801
   PubMedGoogle Scholar
• Wang S, Wu C, Ma D, et al. Identification of a ferroptosis-related gene signature (FRGS) for predicting clinical outcome in lung adenocarcinoma. PeerJ. 2021;9:e11233. doi:10.7717/peerj.11233
   PubMed Web of Science ®Google Scholar
• Ge M, Niu J, Hu P, et al. A ferroptosis-related signature robustly predicts clinical outcomes and associates with immune microenvironment for thyroid cancer. Front Med (Lausanne). 2021;8:637743. doi:10.3389/fmed.2021.637743
   PubMed Web of Science ®Google Scholar
• Deng W, Lira V, Hudson TE, et al. Recombinant Listeria promotes tumor rejection by CD8(+) T cell-dependent remodeling of the tumor microenvironment. Proc Natl Acad Sci U S A. 2018;115(32):8179–8184. doi:10.1073/pnas.1801910115
   PubMed Web of Science ®Google Scholar
• Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 2019;17(1):90. doi:10.1186/s12916-019-1326-5
   PubMed Web of Science ®Google Scholar
• Zheng H, Siddharth S, Parida S, et al. Tumor microenvironment: key players in triple negative breast cancer immunomodulation. Cancers (Basel). 2021;13:13. doi:10.3390/cancers13133357
   Web of Science ®Google Scholar
• Nascimento C, Ferreira F. Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188587. doi:10.1016/j.bbcan.2021.188587
   PubMed Web of Science ®Google Scholar
• Ruth JH, Gurrea-Rubio M, Athukorala KS, et al. CD6 is a target for cancer immunotherapy. JCI Insight. 2021;6:5. doi:10.1172/jci.insight.145662
   Web of Science ®Google Scholar
• Shan CK, Du YB, Zhai XT, et al. Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8(+) T cell augmentation. Cancer Chemother Pharmacol. 2021;87(3):425–436. doi:10.1007/s00280-020-04209-7
   PubMed Web of Science ®Google Scholar
• Buque A, Bloy N, Petroni G, et al. NK cells beat T cells at early breast cancer control. Oncoimmunology. 2020;9(1):1806010. doi:10.1080/2162402X.2020.1806010
   PubMed Web of Science ®Google Scholar
• Levy EM, Roberti MP, Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol. 2011;2011:676198. doi:10.1155/2011/676198
   PubMedGoogle Scholar
• Ali HR, Provenzano E, Dawson SJ, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536–1543. doi:10.1093/annonc/mdu191
   PubMed Web of Science ®Google Scholar
• Fu Y, Zou T, Shen X, et al. Lipid metabolism in cancer progression and therapeutic strategies. MedComm. 2021;2(1):27–59. doi:10.1002/mco2.27
   PubMedGoogle Scholar
• McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662–673. doi:10.1002/cam4.106
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73(12):3591–3603. doi:10.1158/0008-5472.CAN-12-4100
   PubMed Web of Science ®Google Scholar
• Kamphorst AO, Pillai RN, Yang S, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114(19):4993–4998. doi:10.1073/pnas.1705327114
   PubMed Web of Science ®Google Scholar
• Spirina L, Yurmazov Z, Usynin E, et al. Regulation of immunity in clear cell renal carcinoma: role of PD-1, PD-L1, and PD-L2. Current Issues in Molecular Biology. 2021;43(2):1072–1080. doi:10.3390/cimb43020076
   PubMed Web of Science ®Google Scholar
• Nema R, Kumar A. Sphingosine-1-phosphate catabolizing enzymes predict better prognosis in triple-negative breast cancer patients and correlates with tumor-infiltrating immune cells. Front Mol Biosci. 2021;8:697922. doi:10.3389/fmolb.2021.697922
   PubMed Web of Science ®Google Scholar